Phaseline

Targets › AVBP12A

AVBP12A: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Infectious disease.

Open in Phaseline: the race on AVBP12A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Washington University School of MedicineIvermectin
Glutamate-gated chloride channel modulator
AVBP12APhase 2Onchocercal Subcutaneous Nodule–

Conditions

Onchocercal Subcutaneous Nodule (2)

Modalities

small molecule (1)

Companies

Washington University School of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.